Literature DB >> 9922937

Hemophilia. A new approach to an old disease.

D DiMichele1, E J Neufeld.   

Abstract

The history of hemophilia diagnosis and therapy has been a turbulent one. We are coming full circle, back to the use of genetics as the main diagnostic tool for this disease. Therapeutically, the retroviruses that ravaged one generation of hemophiliac patients now may participate in the cure for the next generation. The hemophilia community hopes that the future of hemophilia care will follow a course guided by this modified quote from James Russell Lowell: "New times demand new measures, and men [and women]. As the world advances and in time outgrows the laws that in our fathers' [and mothers'] days were the best, doubtless after us some purer scheme will be shaped out by wiser man [and women] than we, made wiser by the steady growth of truth."

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9922937     DOI: 10.1016/s0889-8588(05)70054-x

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  11 in total

1.  Extracorporeal membrane oxygenation as a bridge to cardiac transplantation in a patient with cardiomyopathy and hemophilia A.

Authors:  Ravi R Thiagarajan; Stephen J Roth; Steven Margossian; Andrew S Mackie; Ellis J Neufeld; Peter C Laussen; Joseph M Forbess; Elizabeth D Blume
Journal:  Intensive Care Med       Date:  2003-04-29       Impact factor: 17.440

2.  Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A.

Authors:  Farhad Lotfi; Hamid Talebianpour; Khosro Keshavarz; Fatemeh Emadi; Mohammad Reza Bordbar; Peivand Bastani
Journal:  Daru       Date:  2020-04-22       Impact factor: 3.117

3.  Spontaneous Retrovesical Haematoma: A New Region for Haematoma Cause of Abdominal Pain in Haemophilia.

Authors:  Pusem Patir; Huseyin Ucar
Journal:  Indian J Hematol Blood Transfus       Date:  2019-07-01       Impact factor: 0.900

Review 4.  Management of factor VIII inhibitors.

Authors:  Donna M Dimichele
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

5.  Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran.

Authors:  Hamid Reza Rasekh; Ali Imani; Mehran Karimi; Mina Golestani
Journal:  Clinicoecon Outcomes Res       Date:  2011-11-23

6.  Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors.

Authors:  Hussain I Saba; Duc Quang Tran
Journal:  J Blood Med       Date:  2011-05-18

7.  Perioperative management of a patient with hemophilia A and crigler-najjar syndrome.

Authors:  Debesh Bhoi; Lokesh Kashyap
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2013-10

8.  Anesthetic management of patient with hemophilia a undergoing emergency ventriculoperitoneal shunting: A case report and review of literature.

Authors:  Rashid Saeed Khokhar; Altaf Hussain; Mueen Ullah Khan; Muhammad Hajnour; Sadia Qureshi; Mansoor Aqil
Journal:  Saudi J Anaesth       Date:  2016 Oct-Dec

9.  Barriers and perceived limitations to early treatment of hemophilia.

Authors:  Kapil Saxena
Journal:  J Blood Med       Date:  2013-05-16

10.  Mild hemophilia A presaged by recurrent postoperative hemorrhagic complications in an elderly patient.

Authors:  Hajime Ono; Taigen Sase; Hiroshi Takasuna; Yuichiro Tanaka
Journal:  Surg Neurol Int       Date:  2017-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.